Clinical pharmacokinetics of inhaled budesonide

Clinical Pharmacokinetics

Volumn 40, Issue 6, 2001, Pages 427-440

  Donnelly, R ^a   Seale, J P ^b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b University of Sydney   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; CORTICOSTEROID; FLUNISOLIDE; FLUTICASONE PROPIONATE; TRIAMCINOLONE ACETONIDE;

AREA UNDER THE CURVE; ASTHMA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; GASTROINTESTINAL ABSORPTION; HUMAN; METERED DOSE INHALER; PRIORITY JOURNAL; REVIEW;

EID: 0034934295     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200140060-00004     Document Type: Review

References (53)

1. Effects of cortisone on bronchial asthma
2. The use of corticosteroids in the treatment of acute asthma
3. Beclomethasone dipropionate: A new steroid aerosol for the treatment of allergic asthma
4. High dose beclomethasone inhaler in the treatment of asthma
5. Asthma
6. Inhaled glucocorticoids for asthma
7. Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man
8. Determination of (22R, S) budesonide in human plasma by automated liquid chromatography/thermospray mass spectrometry
9. Budesonide: An updated review of its pharmacological properties and therapeutic efficacy in asthma and rhinitis
10. Molecular mechanisms of glucocorticoid action in asthma
11. Anti-inflammatory actions of steroids: Molecular mechanisms
12. Lung function and immunopathological changes after inhaled corticosteroid therapy in asthma
13. Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma
14. An audit of inhaler technique among asthma patients of 34 general practitioners
15. Deposition of pressurised aerosols in the human respiratory tract
16. New perspectives on inhaled drug delivery and systemic bioactivity
17. Lung deposition of budesonide from Turbohaler is twice that from a pressurised metered dose inhaler
18. Importance of the inhalation device on the effect of budesonide
19. Budesonide: A preliminary review of its pharmacodynamic properties and therapeutic efficacy in asthma and rhinitis
20. Pharmacokinetics and pharmacodynamics of inhaled corticosteroids
21. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid
22. Pharmacokinetics of epimeric budesonide and fluticasone propionate after repeat dose inhalation: Intersubject variability in systemic absorption from the lung
23. Dose-proportional pharmacokinetics of budesonide inhaled via Turbuhaler
24. Pharmacodynamics and pharmacokinetics of budesonide: A new nebulised corticosteroid
25. Systemic availability and pharmacokinetics of nebulised budesonide in preschool children
26. Glucocorticoid pharmacokinetics: Principles and clinical applications
27. Biotransformation of the topical glucocorticoids budesonide and beclomethasone 17,21-dipropionate in human liver and lung homogenate
28. Comparison of gamma scintigraphy and a pharmacokinetic technique for assessing pulmonary deposition of terbutaline sulphate delivered by pressurised metered dose inhaler
29. Improvement of pressurised aerosol deposition with Nebuhaler spacer device
30. Lung deposition of budesonide from a pressurised metered-dose inhaler attached to a spacer
31. Lung deposition of budesonide from Turbuhaler in asthmatic children
32. Systemic effect of high dose inhaled steroids: Comparison of beclomethasone dipropionate and budesonide in healthy subjects
33. Corticosteroid treatment of asthma: Now at the crossroads
34. Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: A randomised crossover study
35. What factors determine anti-inflammatory activity and selectivity of inhaled steroids?
36. Pharmacokinetic-pharmacodynamic aspects of aerosol therapy using glucocorticoids as a model
37. Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety
38. Pulmonary targeting of liposomal triamcinolone acetonide phosphate
39. Reversible formation of fatty acid esters of budesonide, an antiasthma glucocorticoid, in human lung and liver microsomes
40. Reversible fatty acid conjugation of budesonide. Novel mechanism for prolonged retention of topically applied steroid in airway tissue
41. Formation of fatty acid conjugates of budesonide in human lung in vivo
42. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid
43. Budesonide is metabolised by cytochrome P450 3A (CYP3A) enzymes in human liver
44. Systemic availability of budesonide after nasal administration of three different formulations: Pressurised aerosol, aqueous pump spray and powder
45. Kinetics of the epimeric glucocorticoid budesonide
46. Lung deposition and systemic availability of budesonide inhaled as nebulised suspension from different nebulisers
47. Pharmacokinetics of budesonide in children with asthma
48. Pharmacokinetic/pharmacodynamic comparison of the inhaled corticosteroids
49. Effects of budesonide and fluticasone on 24-hour plasma cortisol
50. No difference between asthmatic patients and healthy subjects in lung uptake of fluticasone propionate
51. Comparison of the systemic effects of fluticasone propionate and budesonide given by dry powder inhaler between healthy and asthmatic subjects
52. Randomised, double-blind, placebo-controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: The ISOLDE trial